NRG-GY017

Closed to Accrual

Return to Protocol Table

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer

Principal Investigator

Jyoti Mayadev, MD

Status

Closed to Accrual

Date Opened To Accrual

October 26 2018

Date Closed to Accrual

June 11 2020

Disease Site

Gynecologic [GY]

Cervix

Phase

Developmental Therapeutics

Primary Objective

To determine whether differences in sequencing of atezolizumab and chemoradiation result in differential immune activation, as determined by clonal expansion of T cell receptor beta (TCRB) repertoires in peripheral blood on day 21.

Patient Population

Patients with locally advanced cervical cancer.

Target Accrual

Forms

GY017_Formset_20190730.pdf

Study Memos

Safety Reports

Other

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.